Literature DB >> 8360327

Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas.

C J Wikstrand1, S D Stanley, P A Humphrey, C N Pegram, G E Archer, S Kurpad, M Shibuya, D D Bigner.   

Abstract

We have previously demonstrated antibody production to a glioma-associated variant form of the human epidermal growth factor receptor in rabbits that had received a synthetic peptide mimicking the unique primary structure of the variant protein as immunogen. We report here the response of mice, rabbits, goats, and macaques immunized by various protocols to this peptide. Titers to both peptide- and cell-elaborated variant receptor were measured, and the capacity to recognize the variant receptor in human tumor samples was determined. Within the range of species and strains investigated, we demonstrated a variable species-associated response to the peptide (rabbits > mice > goats > rats > macaques). Rabbits and a single goat produced specific, high titer antibody activity to the variant receptor protein following immunization with peptide alone. Murine titers to the parent protein were not appreciable following peptide immunization alone; additional immunization with variant receptor as expressed on cell membranes was used to boost this response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8360327     DOI: 10.1016/0165-5728(93)90246-u

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.

Authors:  J H Sampson; L E Crotty; S Lee; G E Archer; D M Ashley; C J Wikstrand; L P Hale; C Small; G Dranoff; A H Friedman; H S Friedman; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.

Authors:  Michelle Paff; Daniela Alexandru-Abrams; Frank P K Hsu; Daniela A Bota
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.

Authors:  Amy B Heimberger; John H Sampson
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388

4.  MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Authors:  Chien-Tsun Kuan; Kenji Wakiya; James E Herndon; Eric S Lipp; Charles N Pegram; Gregory J Riggins; Ahmed Rasheed; Scott E Szafranski; Roger E McLendon; Carol J Wikstrand; Darell D Bigner
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

Review 5.  Challenges in clinical design of immunotherapy trials for malignant glioma.

Authors:  Cleo E Rolle; Sadhak Sengupta; Maciej S Lesniak
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

Review 6.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal:  Semin Immunol       Date:  2008-06-09       Impact factor: 11.130

Review 7.  Prospects of biological and synthetic pharmacotherapies for glioblastoma.

Authors:  David B Altshuler; Padma Kadiyala; Felipe J Nuñez; Fernando M Nuñez; Stephen Carney; Mahmoud S Alghamri; Maria B Garcia-Fabiani; Antonela S Asad; Alejandro J Nicola Candia; Marianela Candolfi; Joerg Lahann; James J Moon; Anna Schwendeman; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2020-01-20       Impact factor: 4.388

Review 8.  EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.

Authors:  Stefanie Keller; Mirko H H Schmidt
Journal:  Int J Mol Sci       Date:  2017-06-18       Impact factor: 5.923

9.  Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor.

Authors:  S Okamoto; K Yoshikawa; Y Obata; M Shibuya; S Aoki; J Yoshida; T Takahashi
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

10.  Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.

Authors:  Jia Shen; Tao Zhang; Zheng Cheng; Ni Zhu; Hua Wang; Li Lin; Zexia Wang; Haotian Yi; Meichun Hu
Journal:  J Exp Clin Cancer Res       Date:  2018-07-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.